News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
BioSpace News Archive
Browse BioSpace’s published news and press releases by year, month, and day.
169 Results
Year
2005 (24679)
2006 (34770)
2007 (39687)
2008 (39410)
2009 (42118)
2010 (39616)
2011 (38383)
2012 (38416)
2013 (36268)
2014 (39672)
2015 (44431)
2016 (38329)
2017 (37186)
2018 (39119)
2019 (51334)
2020 (57662)
2021 (58720)
2022 (53927)
2023 (42564)
2024 (37440)
2025 (33091)
2026 (29112)
Month
January (3217)
February (3391)
March (3462)
April (3660)
May (4506)
June (2887)
July (2191)
August (2499)
September (2720)
October (3233)
November (3383)
December (2291)
Day
1 (190)
2 (123)
5 (141)
6 (141)
7 (169)
8 (187)
9 (100)
12 (133)
13 (138)
14 (122)
15 (129)
16 (48)
19 (83)
20 (66)
21 (95)
22 (49)
23 (90)
24 (1)
26 (99)
27 (109)
28 (135)
29 (105)
30 (46)
Year
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Month
January
February
March
April
May
June
July
August
September
October
November
December
Day
1
2
5
6
7
8
9
12
13
14
15
16
19
20
21
22
23
24
26
27
28
29
30
Approvals
Servier Gets FDA Approval for First Targeted Therapy for Grade 2 IDH-Mutant Glioma
Servier Pharmaceuticals’ vorasidenib on Tuesday secured the FDA’s green light for the treatment of patients with grade 2 gliomas carrying mutations in the IDH gene.
August 7, 2024
·
2 min read
·
Tristan Manalac
Press Releases
Chromocell Announces Stock Repurchase Plan
August 7, 2024
·
5 min read
Press Releases
Revolo Announces Fireside Chat at Canaccord Genuity’s 44th Annual Growth Conference
August 7, 2024
·
1 min read
Press Releases
Outlook Therapeutics® to Report Financial Results for Third Quarter Fiscal Year 2024 on August 14, 2024 and Host Quarterly Conference Call and Webcast
August 7, 2024
·
1 min read
Press Releases
Vericel to Present at the Canaccord Genuity Growth Conference on Wednesday, August 14, 2024
August 7, 2024
·
1 min read
Press Releases
CorMedix Inc. to Report Second Quarter 2024 Financial Results and Provide a Corporate Update on August 14, 2024
August 7, 2024
·
1 min read
Press Releases
Concord Medical Regains Compliance with NYSE Minimum Price Requirement
August 7, 2024
·
2 min read
Earnings
Novo Lowers Full-Year Profit Guidance Amid Disappointing Q2 Semaglutide Sales
Novo Nordisk’s semaglutide brands Ozempic and Wegovy fell short of analyst expectations in the second quarter, mainly held back by supply headwinds. The company’s shares dropped more than 7% in Wednesday morning trading.
August 7, 2024
·
2 min read
·
Tristan Manalac
Press Releases
Cyclacel Pharmaceuticals to Release Second Quarter 2024 Financial Results
August 7, 2024
·
3 min read
Press Releases
ARS Pharmaceuticals to Participate in the 2024 Wedbush PacGrow Healthcare Conference
August 7, 2024
·
1 min read
Previous
12 of 17
Next
